Physician profile
Chad E Paschall
NPI 1780627034
$4,234.77
in general payments reported to CMS, 2019-2025
17 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $64.45 · 2021: $490 · 2022: $1,083 · 2023: $1,063 · 2024: $793 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.96 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,051.81 | 2021-2025 | |
| Braintree Laboratories, INC. | $577.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $336.10 | 2022-2024 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.59 | 2021-2023 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $216.30 | 2019-2025 | |
| Janssen Biotech, INC. | $216.25 | 2021-2024 | Stelara |
| Olympus America INC. | $204.99 | 2019-2024 | Disposable Grasping Forceps, Disposable Biopsy Forceps, Endoclot Phs |
| Genzyme Corporation | $76.95 | 2022 | |
| Organon LLC | $64.14 | 2022-2023 | Renflexis |
| Ironwood Pharmaceuticals, INC | $50.38 | 2022-2023 | Linzess |
| Qol Medical, LLC | $43.33 | 2022 | |
| Boston Scientific Corporation | $38.10 | 2024 | Spyglass |
| Amgen INC. | $35.56 | 2023 | Avsola, Amjevita |
| Lilly USA, LLC | $24.04 | 2023 | |
| Celgene Corporation | $14.76 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $12.13 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,706.11 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Paschall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.